YMAB Y-mAbs Therapeutics Narxning prognoz qilingan daromadga nisbati
Pediatrik dori vositalarini qat'iy harorat nazorati orqali yetkazib berishning ishonchliligi Y-mAbs Therapeutics (YMAB) ta'minot zanjirlarining barqarorligini ta'minlaydi. Kompaniyaning forward P/S ko'rsatkichi investorlar ishonchining belgisi bo'lib xizmat qiladi, bunda 4.60 ushbu metrikaning joriy darajasini ko'rsatadi. Biznes sinovlarda bioetikaga va ekologik toza chiqindilarni yo'q qilish qoidalariga rioya qiladi, tasdiqlangan dori vositalarining muntazam savdosi esa yangi tadqiqotlar uchun pul oqimini qo'llab-quvvatlaydi.
Y-mAbs Therapeutics kompaniyasining tahliliy kesimlari
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi bo'yicha ma'lumotlar:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- qarzdorlik darajasi va moliyaviy likvidlik ma'lumotlari:
Qarzning xususiy kapitalga nisbati Y-mAbs Therapeutics|YMAB - Uzoq muddatli qarzdorlikning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Y-mAbs Therapeutics|YMAB - Jamlangan qarz majburiyatlari|Qarzning balans qiymatiga nisbati Y-mAbs Corp|YMAB - Uzoq muddatli majburiyatlar miqdori|Kompaniyaning qisqa muddatli qarzlari Y-mAbs Therapeutics|Tezkor likvidlik koeffitsiyenti ymabs.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
YMAB - Kompaniyaning sof daromadi|Kutilayotgan foyda Y-mAbs Therapeutics|YMAB - Kompaniya qiymatining sof foydaga nisbati|Forvard P/E multiplikatori YmAbs|YMAB - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati Y-mAbs Corp|YMAB - Foizlar, soliqlar, eskirish va amortizatsiya chegirilmasdan oldingi foyda|Bir aksiya uchun sof foyda (EPS TTM) Y-mAbs Therapeutics|YMAB - So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi ymabs.com|YMAB - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Y-mAbs Therapeutics
- umumiy tushum va sotuv hajmi ma'lumotlari:
Kompaniyaning jamlanma tahlili:Y-mAbs Therapeutics, Inc. (YMAB)
Institutsional kapital Y-mAbs Therapeutics (YMAB) kompaniyasining jozibadorligini kamyob dori vositalarini tijoratlashtirishdan kutilayotgan pul oqimlari va onkologiya yo'nalishidagi ishlab chiqilayotgan loyihalari prizmasi orqali baholaydi. Biznesning joriy bozor qiymatini prognoz qilingan daromadlar bilan solishtiruvchi forward P/S tendentsiyasini tahlil qilish orqali, investorlar aktivlarning haddan tashqari qimmat baholanganlik darajasini va yangi terapiya usullari tasdiqlanishi bilan bog'liq xatarlarga nisbatan fundamental qiymatning ishonchliligini aniqlaydilar.
Raqobatdosh kompaniyalar
BeiGene - Forvard narx/daromad multiplikatori|Prognoz narxning daromadga nisbati Halozyme Therapeutics, Inc.|RVMD - Narxning prognoz qilingan daromadga nisbati|Ascentage Pharma Corp (AAPG) - Forvard narx/daromad multiplikatori|CGON: Forvard P/S multiplikatori|urogen.com (URGN) - Forvard P/S multiplikatori|BCAX (Bicara Therapeutics) - Forvard P/S multiplikatori|Narxning prognoz qilingan daromadga nisbati PSNL|Narxning prognoz qilingan daromadga nisbati Erasca Corp (ERAS)|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Delcath Corp|Aura Biosciences, Inc. - Forvard narx/daromad multiplikatori|Sotuvga nisbatan forvard narx CADL|ARAY: Forvard narx/daromad multiplikatori|SELLAS Life Sciences - Narxning kutilayotgan daromadga nisbati|ACTU: Forvard P/S multiplikatori|Citius Oncology Inc - Sotuvga nisbatan forvard narx|HURA (TuHURA Biosciences Inc.) - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati protaratx.com TARA|Narxning prognoz qilingan daromadga nisbati Fate Therapeutics (FATE)|WHWK (aadibio.com) - Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori TCRX (TScan Therapeutics, Inc.)|Forvard P/S multiplikatori Champions Oncology Inc CSBR|XBIT - Narxning prognoz qilingan daromadga nisbati|Kelajakdagi narxning daromadga nisbati CVM|OSTX: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati radiopharmtheranostics.com (RADX)|Forvard narx/daromad multiplikatori ARTV|Forvard P/S multiplikatori Adlai Nortye Limited|Forvard narx/daromad multiplikatori VERU (Veru Inc.)|Narxning kutilayotgan daromadga nisbati TPST|Forvard P/S multiplikatori XLO (Xilio Therapeutics)|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Renovaro Biosciences (RENB)|Mural Bio - Forvard P/S multiplikatori|Kairos Pharma Ltd (KAPA) - Forvard narx/daromad multiplikatori|onkuretherapeutics.com (OKUR) - Narxning prognoz qilingan daromadga nisbati|GDTC - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Forvard narx/daromad multiplikatori CRIS|Bozor kapitallashuvining kelajakdagi daromadga nisbati Apollomics Corp APLM|Narxning prognoz qilingan daromadga nisbati Tharimmune Corp (THAR)|Forvard narx/daromad multiplikatori advanbiomed.com ADVB|Forvard P/S multiplikatori GNPX (Genprex, Inc.)|Forvard P/S multiplikatori Calidi Biotherapeutics Inc. CLDI|Sunshine Biopharma, Inc. - Forvard P/S multiplikatori|XBIO: Narxning prognoz qilingan daromadga nisbati|SLRX: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Kitov Pharma|AONC (American Oncology Network Inc) - Forvard P/S multiplikatori|Forvard P/S multiplikatori beigene.com|Narxning prognoz qilingan daromadga nisbati Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Kapitalizatsiyaning prognoz qilingan daromadga nisbati|Forvard P/S multiplikatori ICAD (iCAD)|IKNA - Forvard narx/daromad multiplikatori|Notable Labs, Ltd. - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Viracta Therapeutics|MorphoSys (MOR) - Narxning prognoz qilingan daromadga nisbati|NAYA Biosciences Inc - Sotuvga nisbatan forvard narx|Forvard narx/daromad multiplikatori AAPGV
